Holen Sie sich die Stockscreener-App
14.65
6.46%
-0.83
Schlusskurs vom Vortag:
$15.48
Offen:
$14.81
24-Stunden-Volumen:
10,758
Relative Volume:
0.02
Marktkapitalisierung:
$26.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.00M
KGV:
-0.7395
EPS:
-19.8108
Netto-Cashflow:
$-10.93M
1W Leistung:
+41.27%
1M Leistung:
-6.25%
6M Leistung:
+28.19%
1J Leistung:
-67.68%
1-Tages-Spanne:
$13.41
$14.99
1-Wochen-Bereich:
$9.3118
$15.50
52-Wochen-Spanne:
$3.015
$49.60
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Firmenname
Akari Therapeutics Plc Adr
Sektor
Branche
Telefon
(929) 274-7510
Adresse
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
14.95 | 27.10M | 0 | -28.00M | -10.93M | -19.81 |
VRTX
Vertex Pharmaceuticals Inc
|
518.96 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
665.54 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.65 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.19 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
192.35 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2026-01-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-07-18 | Eingeleitet | Maxim Group | Buy |
| 2019-01-04 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Hochstufung | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Bestätigt | Chardan Capital Markets | Sell |
| 2016-07-11 | Eingeleitet | Chardan Capital Markets | Sell |
Alle ansehen
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Finviz
Akari Therapeutics appoints Patricia LoRusso to advisory board - Investing.com
Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each - Stock Titan
Akari Therapeutics completes $8.3m capital raise in Q2 - Investing.com
AKTXAkari Therapeutics Plc ADR Options - Finviz
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones - Sahm
Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com - Investing.com South Africa
White Lion resale of 2.5M Akari (NASDAQ: AKTX) ADSs under $25M equity deal - Stock Titan
Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX) - TradingView
CLA1 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Akari Therapeutics PLC For: 25 June By Investing.com - Investing.com India
Akari Therapeutics (AKTX) CEO granted stock options tied to ADS and financings - Stock Titan
Akari Therapeutics (AKTX) interim CFO granted new ADS awards - Stock Titan
A4270Y Forecast — Price Target — Prediction for 2027 - TradingView
AKTX Options Chain — NASDAQ:AKTX - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Akari Therapeutics PLC (FRA:CLA1) Valuation - GuruFocus
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Large share issuance and governance votes ahead at Akari (NASDAQ: AKTX) 2026 AGM - Stock Titan
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Diluted earnings per share (diluted EPS) of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Which stocks have an unusual volume on Thursday? - ChartMill
VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Akari Therapeutics Soars as KRAS ADC Data Triggers Rerating - timothysykes.com
Akari Therapeutics (AKTX) AGM June 30, 2026 — equity authorizations, warrants/ADSs - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) sets $5.5M ADS and warrant private placement - Stock Titan
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Friday's session: gap up and gap down stocks - ChartMill
Discover the top movers in Friday's pre-market session. - ChartMill
Akari Therapeutics Announces $5.5 Million Private Placement Offering - Sahm
Akari Therapeutics stock rockets 50% higher on KRAS combination data - Investing.com
Akari Therapeutics prices $5.5 million private placement By Investing.com - Investing.com South Africa
Akari Therapeutics prices $5.5 million private placement - Investing.com
Why Akari Therapeutics Stock Is Surging On Thursday? - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Akari Therapeutics secures European patent for ADC payload - Investing.com
[S-1] Akari Therapeutics Plc Files IPO Registration Statement - Stock Titan
Debt to equity ratio of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Unusual VolumeStock ScreenerNews - Finviz
Akari Therapeutics secures Australian patent for ADC payload By Investing.com - Investing.com South Africa
Akari Therapeutics secures Australian patent for ADC payload - Investing.com India
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors - ChartMill
Maxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital Needs - Insider Monkey
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing - ChartMill
Akari Therapeutics (NASDAQ: AKTX) registers 867,023 ADSs after ADS ratio change - Stock Titan
Finanzdaten der Akari Therapeutics Plc Adr-Aktie (AKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akari Therapeutics Plc Adr-Aktie (AKTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO |
Aug 22 '25 |
Buy |
0.93 |
8,000 |
7,440 |
295,574 |
| Gaslightwala Abizer | CEO |
Aug 25 '25 |
Buy |
0.90 |
3,000 |
2,700 |
298,574 |
0.22%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):